Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05690048
Other study ID # Version 1.0/07.12.2022
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 1, 2024
Est. completion date March 1, 2027

Study information

Verified date January 2023
Source University Hospital Heidelberg
Contact Michael T Dill, PhD
Phone 06221 568611
Email michael.dill@med.uni-heidelberg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The interventional, randomized, placebo-controlled, single blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design. Subjects will be randomized 2:1 into either the FMT or placebo group.


Description:

Eligible HCC patients visiting the outpatient clinics of LCCH at the study sites at NCT Heidelberg and University Medical Center Mannheim will be enrolled into the study after informed consent. Patients undergo 2:1 randomization into either the FMT or placebo group. Study lead in with a first sonographically guided tumor biopsy, if not already performed for diagnostic purposes, and a sigmoidoscopy will be scheduled within 10 days after study enrollment in an outpatient setting. Start of active pharmacotherapy with A/B will begin within five working days after sigmoidoscopy. A/B administration will be administered as standard of care every 21 days. At day -3 to 0 oral Vancomycin will be given 4x 250mg to the verum group. At day 0 and 21, concurrent to the first and second cycle of A/B, encapsulated FMT will be administered on the same day. At day 40-42, before the third cycle of A/B, a second biopsy of the liver lesion and a sigmoidoscopy will be performed. Clinical efficacy and safety will be assessed as indicated per protocol analysis.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 48
Est. completion date March 1, 2027
Est. primary completion date July 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age 18 years or older 2. Confirmed imaging or histological diagnosis of unresectable HCC, BCLC stadium C 3. ECOG performance status of 0-1 Exclusion Criteria: 1. Advanced liver cirrhosis (Child-Pugh Score C) 2. Diagnosis of immunodeficiency (e.g. HIV, immunosuppressants) 3. Usage of antibiotics within 2 weeks prior enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fecal microbiota transfer
FMT via capsule (50 g of fecal matter) on day 0 and day 21.
Vancomycin Oral Capsule
Vancomycin orally (125 mg 4xd, day -3 to 0).
Atezolizumab + Bevacizumab
Atezolizumab 1200mg i.v. & Bevacizumab 15mg/kg body weight i.v. (A/B) as standard of care (SOC).
Placebo Vancomycin Oral Capsule
Placebo Vancomycin orally (125 mg 4xd, day -3 to 0).
Placebo Fecal microbiota transfer
Placebo Fecal microbiota transfer (FMT) via capsule (50 g of fecal matter) on day 0 and day 21.

Locations

Country Name City State
Germany University Hospital Heidelberg Heidelberg Baden-Württemberg
Germany University Hospital Heidelberg Heidelberg Baden-Württemberg

Sponsors (6)

Lead Sponsor Collaborator
Michael Dill German Cancer Research Center, Heidelberg University, National Center for Tumor Diseases, Heidelberg, Universitätsmedizin Mannheim, University of Cologne

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Differential tumoral CD8 T-cell infiltration Tumoral CD8 T-cells in IHC before treatment initiation and 6 weeks after (CD8-cells/area of tumor tissue in formalin embedded tumor tissue) 6 weeks after treatment initiation
Primary Adverse event documentation of FMT in advanced HCC Adverse event documentation [AE] & immune-related adverse events [irAE]) Follow up 3 months after treatment initiation
Secondary Progression-free survival (PFS) Progression-free survival as by RECIST1.1 criteria Follow up 3 months after treatment initiation
Secondary Overall survival (OS) Overall survival Follow up 12 months after treatment initiation
Secondary Change of Hepatic function Assessment of Model of End-Stage Liver Disease Score in blood (MELD-Score, 6-40, higher score refers to worse hepatic function) Follow up 3 months after treatment initiation
See also
  Status Clinical Trial Phase
Recruiting NCT05848011 - A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05161572 - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer Phase 2
Recruiting NCT06165900 - Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC Phase 2
Recruiting NCT06120127 - Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence Phase 2
Recruiting NCT06262581 - Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery Phase 2
Recruiting NCT05176002 - Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. Phase 1/Phase 2
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Recruiting NCT04500990 - MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study
Not yet recruiting NCT04372732 - Serum Autoantibodies in Predicting the Efficacy of Anti-PD-1 Treatment in Patients With Advanced NSCLC
Completed NCT02692976 - Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients Phase 2
Completed NCT03763630 - MAPS & ITEC Cohorts: 6-8 Years Follow-up Phase 2
Not yet recruiting NCT06012318 - Dynamic Follow-up of Symptoms Based on Patient-reported Outcomes in Immunotherapy for Esophageal Cancer: a Prospective Multicentre Cohort Study (SPRING)
Not yet recruiting NCT05479240 - Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer Phase 2
Recruiting NCT04711330 - Response and Toxicity Prediction by Microbiome Analysis After Concurrent Chemoradiotherapy
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Recruiting NCT03683407 - Effect of Chemotherapy on TMB in NSCLC
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Completed NCT03357861 - Cancer Patients Treated With Immunotherapy in Intensive Care Unit
Recruiting NCT05223088 - Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer Phase 2
Completed NCT05657262 - Effect of Z Technıque on Pain, Comfort, Symptoms in Ummunotherapy Areas N/A